Etomidate Dose for Rapid Sequence Intubation
For rapid sequence intubation, administer etomidate 0.3 mg/kg IV over 30-60 seconds in adults and children over 10 years of age. This is the FDA-approved standard induction dose that balances efficacy with safety 1.
Dosing by Population
Adults and Children >10 Years
- Standard dose: 0.3 mg/kg IV (range 0.2-0.6 mg/kg) 1
- Inject over 30-60 seconds
- This dose provides reliable intubation conditions with minimal hemodynamic changes 2
Pediatric Patients <10 Years
The FDA label states there are inadequate data for dosing recommendations in children under 10 years, and such use is "not recommended" 1. However, real-world evidence strongly supports using 0.3 mg/kg in this age group when RSI is needed:
- Multiple studies demonstrate safety and efficacy at 0.3 mg/kg in children <10 years 2, 3
- Produces minimal hemodynamic changes (mean BP increase of 4 mmHg systolic, 7 mmHg diastolic) 3
- Mean dose of 0.37 mg/kg used successfully in 100 pediatric patients <10 years with only 1% decrease in blood pressure 2
- No clinically significant adrenal suppression requiring treatment 2, 3
The 2015 AHA Pediatric Advanced Life Support Guidelines explicitly recommend AGAINST routine use of etomidate in pediatric septic shock (Class III recommendation) 4, though a single dose for RSI appears safe in other contexts.
Critical Dosing Considerations
Weight-Based Dosing Errors
Patients ≥100 kg are at high risk for under-dosing. In one study, 68% of patients ≥100 kg received <0.2 mg/kg (considered under-dosing) compared to only 2% of patients <100 kg 5. Calculate the actual weight-based dose rather than using fixed maximum doses.
Dose and Hypotension
The etomidate dose (within the therapeutic range) is NOT independently associated with post-intubation hypotension 6. In a registry of 12,175 intubations, neither etomidate dose (aOR 0.95) nor ketamine dose (aOR 0.97) correlated with post-intubation hypotension. This challenges the common practice of empirically reducing sedative doses in hemodynamically unstable patients.
Hemodynamic Profile
Etomidate has the most favorable hemodynamic profile among induction agents:
- Minimal effect on blood pressure (1% mean decrease in pediatric RSI) 2
- Slight increase in heart rate (average 10 beats/min) 3
- Preserves cardiac output and peripheral circulation 1
- Superior to propofol and comparable to ketamine for hemodynamic stability 7, 8
However, geriatric patients with hypertension may experience decreases in heart rate, cardiac index, and mean arterial pressure 1.
Adrenal Suppression Controversy
Single-dose etomidate causes transient adrenal enzyme inhibition lasting 6-8 hours 1, but clinical significance remains unclear:
- No patients required corticosteroid replacement for suspected adrenal insufficiency in multiple pediatric studies 2, 3
- Cortisol levels remain within normal laboratory ranges despite blunted ACTH response 2
- A 2023 meta-analysis showed increased mortality with etomidate (RR 1.09), but this was heavily confounded by selection bias and severity of illness 7
- The 2023 SCCM guidelines found no mortality difference in high-quality studies (Cochrane review: OR 1.17,95% CI 0.86-1.60) 7
For septic patients specifically, consider ketamine as an alternative given the AHA recommendation against etomidate in pediatric septic shock 4 and theoretical concerns about adrenal suppression in critical illness.
Practical Administration
- Onset: Within 1 minute 1
- Duration: 3-5 minutes at 0.3 mg/kg 1
- Preparation: Inspect for particulate matter; discard if solution is not clear 1
- Route: IV only; do not use IM 1
- Adjuncts: Compatible with standard premedications and neuromuscular blockers 1
Common Adverse Effects
- Myoclonus (4-8% in pediatric studies) 2
- Transient elevation in PaCO2 1
- Vomiting (<3% in children) 3
- Pain on injection (rare) 2
Alternative Agents for Comparison
When etomidate is contraindicated or unavailable: